Indoco Remedies Limited on Friday said its Goa Unit-I manufacturing facility has received EU Good Manufacturing Practice (GMP) certification following an inspection by the Malta Medicines Authority.
In a regulatory filing, the company said the audit of the solid oral dosage facility (Plant I) at Goa was conducted between November 19 and November 24, 2025, and the certification confirms compliance with GMP requirements under the applicable European Commission directive.
The approval strengthens Indoco’s regulatory standing in Europe and supports its plans to expand exports to regulated markets. Commenting on the development, Aditi Panandikar, Managing Director – Indoco Remedies Ltd., said, “Compliance is a core value that drives our quality systems. This approval reinforces our commitment to delivering the highest quality healthcare to our customers worldwide.”
